TNF and cancer: There was no significant difference in the risk of malignant neoplasms between JAK inhibitors vs TNF antagonists (pooled HR, 1.02 [95% CI, 0.90-1.16]), with low heterogeneity (I2 = 6.0%) (Figure 2).